FDA-grade potential Structure offers an AI-native, software-defined diagnosis platform that accelerates medical device development from years and millions to months and lower costs. This positions the company to target medical device manufacturers and hospital systems seeking rapid regulatory clearance and faster time-to-market for diagnostic apps.

iOS to devices The platform converts mobile iOS app code into deployable medical devices, suggesting upsell opportunities with mobile health developers, digital health startups, and integrators looking to modernize or scale existing iOS apps into regulated medical-grade solutions.

Regulatory momentum With several partners obtaining regulatory clearances and a track record of clinically used deployments, Structure can leverage credibility to approach device manufacturers and clinical networks pursuing FDA-aligned software solutions and regulatory support services.

Health-tech traction Currently powering over 350 apps and enabling millions of patient scans per year through partner implementations, presenting a strong reference base for enterprise sales to large health systems, imaging centers, and medtech collaborators seeking scalable AI-native diagnosis infrastructure.

Expansion-ready platform The platform’s capability to host 4x faster development and significantly reduced cost creates cross-sell opportunities to expand within existing customers, as well as to attract healthcare developers and AI/ML teams looking to modernize diagnostics pipelines and regulatory-grade deployment.